Journal of Clinical and Aesthetic Dermatology

MauiDerm 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/824994

Contents of this Issue

Navigation

Page 29 of 31

JCAD S30 journal of clinical and aesthetic dermatology JCAD journal of clinical and aesthetic dermatology May 2017 • Volume 10 • Number 5 (Supplement 1) BY ARTICLE TITLE A Phase 2, Multicenter, Double-blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.....................................S17 A Retrospective Cohort Study of Real-world Experience with Apremilast in Patients with Moderate to Severe Plaque Psoriasis.......................................................... S25 Assessment of Efficacy and Irritation of Ingenol Mebutate Gel, 0.015%, Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face................... S8 Defining Field Cancerization of the Skin Using Noninvasive Optical Coherence Tomography Imaging to Detect and Monitor Actinic Keratosis in Ingenol Mebutate 0.015%- Treated Patients—The Extension Study....................... S8 DFD-01, a Midpotent Betamethasone Dipropionate 0.05% in an Emollient-like Spray Formulation, Demonstrates Similar Efficacy to a Super Potent Topical Steroid for the Treatment of Moderate Psoriasis................................ S16 DFD-01, an Emollient-Like Spray Formulation of 0.05% Betamethasone Dipropionate, Effectively Treats Plaque Psoriasis on Knees and Elbows................................... S29 DRM04 For the Treatment of Primary Axillary Hyperhidrosis: Primary Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials......... S10 Ease of Use and Confidence Using Auto-Injector to Administer Ixekizumab in a Phase 3 Trial Evaluated with Subcutaneous Administration Assessment Questionnaire (SQAAQ)......................................................................S14 Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase 4 Study)............................................................S26 Efficacy and Safety of Continuous Ixekizumab Treatment for 60 Weeks in Moderate-to-Severe Plaque Psoriasis: Results from the UNCOVER-3 Trial...............................S15 Effectiveness and Tolerability of a Novel Large Molecule, Injectable-grade Hyaluronic Acid Cream in Subjects with Moderate Photoaging.................................................S12 Evaluation of a Double Conjugate Retinoid Cream vs. Retinol or Tretinoin Cream in Subjects with Photodamage............................................................ S11 Imiquimod 2.5% and 3.75% for the Treatment of Photodamage: Meta-Analysis of Efficacy and Tolerability i n 969 Randomized Patients....................................... S12 Impact of Previous Biologic Use and Failure on Efficacy of Brodalumab and Ustekinumab: A Pooled Analysis of Data from Two Phase 3 Randomized Clinical Trials in Moderate-to-severe Plaque Psoriasis (AMAGINE-2 and AMAGINE-3)............................................................... S23 Improvements in Lesional Burning and Stinging With Brodalumab in Psoriasis Studies................................. S13 Integrated Safety of Ixekizumab in Patients with Moderate-to-severe Psoriasis: Results from a Pooled Analysis of 7 Clinical Trials.......................................... S21 Ixekizumab in Patients with Moderate-to-severe Psoriasis who Have or Have Not Received Prior Biologic Therapies: an Integrated Analysis of 2 Phase III Studies.............. S27 Long-term Psoriasis Control Following Secukinumab Discontinuation Indicates Disease Modification of Moderate to Severe Psoriasis ..................................... S28 Maintenance of Clinical Efficacy in Moderate-to-severe Plaque Psoriasis: A 52-week Evaluation of Brodalumab in Three Multicenter, Double-blind Studies of 4363 Subjects...................................................................... S23 Median Time to Treatment Response in Patients with Moderate-to-severe Plaque Psoriasis Treated with Brodalumab 210mg or Ustekinumab: A Pooled Analysis of Data from Two Phase 3 Randomized Clinical Trials (AMAGINE-2 and AMAGINE-3).................................... S22 Olumacostat Glasaretil (DRM01) for the Treatment of Acne Vulgaris: Primary Results from the DRM01-ACN02 Phase 2b Randomized Controlled Trial......................................... S7 Rapid Onset of Efficacy in Patients with Psoriasis Treated with Ixekizumab: A Pooled Analysis of Data from Two Phase 3 Randomized Clinical Trials (UNCOVER-2 and UNCOVER-3)............................................................... S26 Safety and Efficacy of Apremilast through 104 Weeks in Patients with Moderate to Severe Psoriasis who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study.................................................... S24 Secukinumab 300mg is More Efficacious than Ustekinumab 90mg: Analysis of the CLEAR Study...... S18 Secukinumab Demonstrates Sustained High Efficacy and a Favorable Safety Profile in Moderate to Severe Psoriasis Patients Through 4-Years of Treatment (Extension of the SCULPTURE Study) ..................................................... S18 Secukinumab Improves Signs and Symptoms of Psoriatic Arthritis: 52-week Results of Phase 3 FUTURE 2 Study Stratified by Concomitant Methotrexate Use.............. S19 Secukinumab is Effective in Subjects With Moderate to Severe Palmoplantar Psoriasis: 1.5 Year Results From the GESTURE Study........................................................... S20 Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results From the TRANSFIGURE Study..........S21 Secukinumab Treatment Provides Faster and More Effective Relief From Patient-reported Quality of Life Impact than Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis......................................................................S15 Survey Study of Dermatologist and Patient Satisfaction with Halobetasol Propionate Lotion for the Treatment of Plaque Psoriasis.......................................................... S27 The Efficacy and Safety of Desoximethasone 0.25% Spray in Adult Atopic Dermatitis Subjects—A Pilot Study...S10 The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis.......................................S9 Alphabetical Index of Posters

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - MauiDerm 2017